Despite the recent use of novel therapies including proteasome inhibitors, i.e., bortezomib (btz), immunomodulatory drugs (IMiDs), i.e., lenalidomide (len) and pomalidomide (pom), and monoclonal antibodies (mAbs), i.e., daratumumab (dara) and isatuximab targeting CD38, alone or in combination, MM remains an incurable disease in most patients due to the development of drug resistance underlying relapse of disease3,4. Here, CD38 is linked to Miyoshi myopathy.